Tag Archives: low-density lipoprotein (LDL) cholesterol
October 2019 Br J Cardiol 2019;26:137–40 doi:10.5837/bjc.2019.036
PCSK9 inhibitors in familial hypercholesterolaemia: a real-world experience and a meta-analysis
Harshal Deshmukh, Deepa Narayanan, Maria Papageorgiou, Yvonne Holloway, Sadaf Ali, Thozhukat Sathyapalan
Introduction Familial hypercholesterolaemia (FH) is a monogenic disorder characterised by excessive levels of low-density lipoprotein-cholesterol (LDL-C) and associated with significant cardiovascular morbidity and mortality.1 A reduction in LDL-C levels is the mainstay of treatment in FH and evidence-based guidelines have proposed treatment goals for these patients. The National Institute for Health and Care Excellence (NICE) recommends at least a 50% reduction in LDL-C levels from the baseline measurement in patients with FH,2 while the European Atherosclerosis Society and the International FH Foundation suggest target LDL-C levels of <2
September 2002 Br J Cardiol 2002;9:469-75
Extended-release fluvastatin 80 mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40 mg for once daily treatment of primary hypercholesterolaemia
Donald B Hunninghake, Michael Davidson, Howard R Knapp, Helmut G Schrott, Sheryl Manfreda, and the Fluvastatin Study Group
No content available
For healthcare professionals only
